Multivariate analysis revealed that never smoking (HR, 1.77; 95% CI, 1.15‐2.75), CRP ≥ 1 mg/dL (HR, 1.39; 95% CI, 1.00‐1.93), liver metastasis (HR, 1.95; 95% CI, 1.24‐3.07), pleural effusion (HR, 1.45; 95% CI, 1.06‐2.00), and steroid use (HR, 2.85; 95% CI, 1.65‐4.94) were significantly associated with a shorter PFS among patients with NSCLC treated with nivolumab with good PS. This evidence concerns the gene CRP and non-small cell lung carcinoma.